www.sciencetranslationalmedicine.org/cgi/content/full/3/109/109ra115/DC1

Supplementary Materials for

Treatment and Prevention of Urinary Tract Infection with Orally Active FimH Inhibitors

Corinne K. Cusumano, Jerome S. Pinkner, Zhenfu Han, Sarah E. Greene, Bradley A. Ford, Jan R. Crowley, Jeffrey P. Henderson, James W. Janetka,* Scott J. Hultgren*

*To whom correspondence should be addressed. E-mail: hultgren@borcim.wustl.edu (S.J.H.); janetkaj@biochem.wustl.edu (J.W.J.)

Published 16 November 2011, *Sci. Transl. Med.* **3**, 109ra115 (2011)
DOI: 10.1126/scitranslmed.3003021

The PDF file includes:



Figure S1: Minimal degradation of compound 6 occurs after oral gavage. Pharmacokinetic analysis of **6** ($n \geq 3$ mice) showing concentration of intact compound **6** and it's R-group degradation product in urine over time after a 100 mg/kg dose. The only detectable metabolism of the mannoside was hydrolysis of the glycosidic bond (yielding D-mannose and the phenol) but >95% of drug was excreted in the urine unchanged.